HOME >> MEDICINE >> NEWS
Neurobiology of dread gives scientists clues about human decision making

ATLANTA -- In order to better understand how people make decisions when the outcomes are known to be unpleasant, a team of Emory neuroscientists led by Gregory Berns, MD, PhD, used functional magnetic resonance imaging (fMRI) to determine the areas of the brain that are activated when someone experiences dread. The study, which was supported by the National Institutes of Drug Abuse (NIDA), was published in the May 5, 2006 issue of the journal Science. The study was part of a research program in the growing field of neuroeconomics, an area in which neuroscience methods are being applied to economic questions.

"Most people don't like waiting for an unpleasant outcome, and want to get it over with as soon as possible," explains Dr. Berns, an associate professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. "The only explanation for this is that the dread of having something hanging over your head is worse than the thing that you are dreading. It is a commonplace experience, but standard economic models of decision-making don't deal with this issue. So, we decided to take a biological approach and see what happens in the brain that might cause people to make such rash decisions."

The study was conducted using an fMRI scanner to look at the brains of the study participants while delivering a series of low voltage shocks to the foot of each participant, with different levels of intensity and different time delays up to the shock. Each of the participants in the study was screened to determine their maximal pain threshold. While in the MRI scanner, participants underwent a series of 96 shocks. Before each shock, they were told how painful the shock would be (as a percent of their threshold) and how long they would have to wait for it. After the scanning procedure, they were then given the opportunity to choose between different intensity-delay combinations, the choice was always between more pain s
'"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University Health Sciences Center
4-May-2006


Page: 1 2 3

Related medicine news :

1. Once-dreaded leprosy replaced by tuberculosis, say researchers
2. Dyson Foundation gives $5 Million for ophthalmology research at Weill Cornell Medical College
3. Thymus transplants gives hope to babies with fatal immune disease
4. Plasmonics book gives overview of technology that could revolutionize computing
5. Study of leukemia survivors gives hints for better care
6. New Inteleos features gives users the ability to tailor information
7. Breast cancer treatment procedure gives women more options
8. Woodruff Foundation gives major boost to Emory Universitys strategic plan
9. Core needle biopsy gives an accurate picture of gene expression in whole tumor
10. NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
11. National trial gives unprecedented support for steroid withdrawal in kidney transplants

Post Your Comments:
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... The Institute for Integrative Nutrition (IIN), ... Arianna Huffington has joined as a guest speaker and is ... Training Program . , Arianna Huffington is the chair, president, ... blogging site that won a Pulitzer Prize in 2012 for ... was included on the Forbes “Most Powerful Women” list of ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- For patients with ... enough to trigger airway inflammation for at least 24 ... what you smell, but also what you think you ... Chemical Senses Center in Philadelphia, said in a Monell ... scents and fragrances. When we expect that an odor ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
(Date:7/30/2014)... 30, 2014   Epic Sciences, Inc. ... and develops novel diagnostics to personalize and advance ... the completion of a $30 million Series C ... RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain ... as well as undisclosed individual investors. With the ...
(Date:7/30/2014)... 2014 Die Apex Medical Corporation ... Bereich Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass ... Deutschland anfechten werden. Dieses hat entschieden, dass ... von ResMed verletze. Apex weist darauf hin, ... verschiedene Patente von ResMed Anfechtungen wegen Nichtigkeit ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
Cached News: